Research programme: 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors - Connexios

Drug Profile

Research programme: 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors - Connexios

Alternative Names: CNX-010; CNX-010-49

Latest Information Update: 09 May 2014

Price : $50

At a glance

  • Originator Connexios Life Sciences
  • Class Small molecules
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 09 May 2014 Preclinical development is ongoing in India
  • 09 May 2014 This programme is available for partnering or licensing as of 09 May 2014.
  • 20 Oct 2009 Preclinical trials in Type-2 diabetes mellitus (in the elderly) in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top